Presentation is loading. Please wait.

Presentation is loading. Please wait.

Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Published byRobyn Hunt Modified over 8 years ago

Similar presentations

Presentation on theme: "Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients."— Presentation transcript:

1 Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL Characteristic Coronary events/total patients (%) RR (95% CI) Pravastatin(n=1316)Placebo(n=1291) Age 60 y 178/790 (23) 187/788 (24) 0.96 (0.78–1.17) Age <60 y 106/526 (20) 105/503 (21) 0.96 (0.74–1.26) Women 26/170 (15) 30/147 (20) 0.74 (0.44–1.26) Men 258/1146 (23) 262/1144 (23) 0.98 (0.83–1.17) HTN 138/549 (25) 158/594 (27) 0.94 (0.75–1.18) No HTN 146/767 (19) 134/697 (19) 0.99 (0.79–1.26) Diabetes 39/181 (22) 65/189 (34) 0.56 (0.37–0.83)* No diabetes 245/1135 (22) 227/1102 (21) 1.06 (0.89–1.27) *p=.004; p=.005 for interaction Sacks FM et al. Circulation 2002;105:1424-1428.

2 Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL Characteristic Coronary events/total patients (%) RR (95% CI) Pravastatin(n=1316)Placebo(n=1291) BMI 27 kg/m 2 147/612 (24) 154/596 (26) 0.92 (0.73–1.15) BMI <27 kg/m 2 136/702 (19) 137/693 (20) 0.98 (0.77–1.24) HDL-C <40 mg/dL 217/945 (23) 240/900 (27) 0.84 (0.70–1.01)* HDL-C 40 mg/dL 67/371 (18) 52/391 (13) 1.42 (0.99–2.04) TG 150 mg/dL 160/638 (25) 159/626 (25) 0.98 (0.79–1.23) TG <150 mg/dL 124/678 (18) 133/665 (20) 0.91 (0.71–1.17) Smoking 24/123 (20) 40/137 (29) 0.63 (0.38–1.05)† Nonsmoking 260/1193 (22) 252/1154 (22) 1.00 (0.84–1.19) *p=.06 for RR in HDL-C groups and for interaction (HDL-C as continuous variable) †p=0.075; p=.09 for interaction Sacks FM et al. Circulation 2002;105:1424-1428.

3 Slide Source: Lipids Online Slide Library www.lipidsonline.org >60 Coronary Event Rate (%) Sacks FM et al. Circulation 2002;105:1424-1428. Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients with Baseline LDL-C <125 mg/dL <60FM+—+—+—>27<27<40>40 >150<150 AgeSexHTNSmokingDMBMIHDL-CTG ** * Pravastatin Placebo *p=.004 *p=.004 **p (interaction) =.005

4 Slide Source: Lipids Online Slide Library www.lipidsonline.org Cumulative Coronary Event Rates in Diabetic and Nondiabetic Patients with Baseline LDL-C <125 mg/dL Cumulative Risk of Coronary Event or Procedure (%) Years Follow-up Sacks FM et al. Circulation 2002;105:1424-1428. 01234675 Placebo Diabetic Pravastatin Nondiabetic Pravastatin Diabetic Placebo Nondiabetic

Download ppt "Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients."

Similar presentations

1 Baseline BMI and Age-Adjusted Incidence of Diabetes Mellitus White Men Level of BMI Percent 35 30 25 20 15 10 5 0

1 Baseline BMI and Age-Adjusted Incidence of Diabetes Mellitus White Men Level of BMI Percent
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.

OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345:1291-7. Incidence of CV events in women.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Lipid Disorders and Management in Diabetes

Lipid Disorders and Management in Diabetes
Slide Source LipidsOnline www.lipidsonline.org CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.

Slide Source LipidsOnline CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.
Slide Source: Lipids Online Slide Library www.lipidsonline.org 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.

Slide Source: Lipids Online Slide Library 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Slide Source: Lipids Online Slide Library www.lipidsonline.org High-Density Lipoprotein and the Epidemiology of Coronary Heart Disease Michael Miller,

Slide Source: Lipids Online Slide Library High-Density Lipoprotein and the Epidemiology of Coronary Heart Disease Michael Miller,
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Slide Source: Lipids Online Slide Library www.lipidsonline.org Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
TC LDL- C HDL- C Nonfatal MI/CHD death CHD death All- cause mortality *As compared to placebo. † P=0.003. CARE: Effect of Lipid Lowering on Lipid Values.

TC LDL- C HDL- C Nonfatal MI/CHD death CHD death All- cause mortality *As compared to placebo. † P= CARE: Effect of Lipid Lowering on Lipid Values.
LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.

LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.
TM © 1999 Professional Postgraduate Services ® 0.60 0.70 0.80 0.90 1.00 4S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.

TM © 1999 Professional Postgraduate Services ® S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:757-767.

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:
Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.

Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.

Similar presentations

Ads by Google